

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 June 2010 (17.06.2010)

(10) International Publication Number
WO 2010/068480 A1

PCT

(51) International Patent Classification:

C07D 471/04 (2006.01) **A61P 25/28** (2006.01)
A61K 31/475 (2006.01)

(21) International Application Number:

PCT/US2009/065872

(22) International Filing Date:

25 November 2009 (25.11.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/200,206 25 November 2008 (25.11.2008) US

(71) Applicant (for all designated States except US): **CONCERN PHARMACEUTICALS, INC.** [US/US]; 99 Hayden Avenue, Suite 500, Lexington, Massachusetts 02421 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SILVERMAN, I., Robert** [US/US]; 36 Orvis Road, Arlington, Massachusetts 021474 (US). **MASSE, Craig, E.** [US/US]; 122 Hamilton Street #2, Cambridge, Massachusetts 02139 (US).

(74) Agents: **DAVIS, Steven, G.** et al.; Foley & Lardner LLP, 111 Huntington Avenue, Boston, Massachusetts 02199 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: DEUTERATED DERIVATIVES OF DIMEBOLINE

(57) Abstract: This invention relates to novel tetrahydro-1H-pyrido[4,3-b]indoles, their derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by NMDA antagonists, acetylcholinesterase inhibitors, 5-HT₆ antagonists, other neuroprotectors, antihistamines and agents that delay age-related pathologies and conditions.



WO 2010/068480 A1

DEUTERATED DERIVATIVES OF DIMEBOLINE

RELATED APPLICATION

[1] The application claims priority to U.S. Provisional Application No. 61/200,206, filed November 25, 2008, which is incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

[2] Many current medicines suffer from poor absorption, distribution, metabolism and/or excretion (ADME) properties that prevent their wider use. Poor ADME properties are also a major reason for the failure of drug candidates in clinical trials. While formulation technologies and prodrug strategies can be employed in some cases to improve certain ADME properties, these approaches often fail to address the underlying ADME problems that exist for many drugs and drug candidates. One such problem is rapid metabolism that causes a number of drugs, which otherwise would be highly effective in treating a disease, to be cleared too rapidly from the body. A possible solution to rapid drug clearance is frequent or high dosing to attain a sufficiently high plasma level of drug. This, however, introduces a number of potential treatment problems such as poor patient compliance with the dosing regimen, side effects that become more acute with higher doses, and increased cost of treatment.

[3] In some select cases, a metabolic inhibitor will be co-administered with a drug that is cleared too rapidly. Such is the case with the protease inhibitor class of drugs that are used to treat HIV infection. The FDA recommends that these drugs be co-dosed with ritonavir, an inhibitor of cytochrome P450 enzyme 3A4 (CYP3A4), the enzyme typically responsible for their metabolism (see Kempf, D.J. et al., *Antimicrobial agents and chemotherapy*, 1997, 41(3): 654-60). Ritonavir, however, causes adverse effects and adds to the pill burden for HIV patients who must already take a combination of different drugs. Similarly, the CYP2D6 inhibitor quinidine has been added to dextromethorphan for the purpose of reducing rapid CYP2D6 metabolism of dextromethorphan in a treatment of pseudobulbar affect. Quinidine, however, has

unwanted side effects that greatly limit its use in potential combination therapy (see Wang, L et al., Clinical Pharmacology and Therapeutics, 1994, 56(6 Pt 1): 659-67; and FDA label for quinidine at www.accessdata.fda.gov).

[4] In general, combining drugs with cytochrome P450 inhibitors is not a satisfactory strategy for decreasing drug clearance. The inhibition of a CYP enzyme's activity can affect the metabolism and clearance of other drugs metabolized by that same enzyme. CYP inhibition can cause other drugs to accumulate in the body to toxic levels.

[5] A potentially attractive strategy for improving a drug's metabolic properties is deuterium modification. In this approach, one attempts to slow the CYP-mediated metabolism of a drug by replacing one or more hydrogen atoms with deuterium atoms. Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Compared to hydrogen, deuterium forms stronger bonds with carbon. In select cases, the increased bond strength imparted by deuterium can positively impact the ADME properties of a drug, creating the potential for improved drug efficacy, safety, and/or tolerability. At the same time, because the size and shape of deuterium are essentially identical to those of hydrogen, replacement of hydrogen by deuterium would not be expected to affect the biochemical potency and selectivity of the drug as compared to the original chemical entity that contains only hydrogen.

[6] Over the past 35 years, the effects of deuterium substitution on the rate of metabolism have been reported for a very small percentage of approved drugs (see, e.g., Blake, MI et al, J Pharm Sci, 1975, 64:367-91; Foster, AB, Adv Drug Res 1985, 14:1-40 ("Foster"); Kushner, DJ et al, Can J Physiol Pharmacol 1999, 79-88; Fisher, MB et al, Curr Opin Drug Discov Devel, 2006, 9:101-09 ("Fisher")). The results have been variable and unpredictable. For some compounds deuteration caused decreased metabolic clearance *in vivo*. For others, there was no change in metabolism. Still others demonstrated increased metabolic clearance. The variability in deuterium effects has also led experts to question or dismiss deuterium modification as a viable drug design strategy for inhibiting adverse metabolism (see Foster at p. 35 and Fisher at p. 101).

[7] The effects of deuterium modification on a drug's metabolic properties are not predictable even when deuterium atoms are incorporated at known sites of metabolism. Only by actually preparing and testing a deuterated drug can one determine if and how the rate of metabolism will differ from that of its non-deuterated counterpart. *See*, for example, Fukuto et al. (J. Med. Chem. 1991, 34, 2871-76). Many drugs have multiple sites where metabolism is possible. The site(s) where deuterium substitution is required and the extent of deuteration necessary to see an effect on metabolism, if any, will be different for each drug.

[8] Dimebolin, also known as dimebon and 2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride, has a wide array of biological activities including antihistamine properties, NMDA antagonism, delay of age-related pathologies and conditions, and neuroprotection modulates.

[9] Dimebolin is currently in Phase III trials for Huntington's disease and Phase III trials for Alzheimer's-type dementia. Dimebolin has been used to treat allergic rhinitis and skin allergies in Russia for the past 25 years.

[10] Despite the beneficial activities of dimebolin, there is a continuing need for new compounds to treat the aforementioned diseases and conditions.

SUMMARY OF THE INVENTION

[11] This invention relates to novel tetrahydro-1H-pyrido[4,3-b]indoles, their derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by NMDA antagonists, acetylcholinesterase inhibitors, 5-HT₆ antagonists, other neuroprotectors, antihistamines and agents that delay age-related pathologies and conditions.

DETAILED DESCRIPTION OF THE INVENTION

[12] The terms "ameliorate" and "treat" mean decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease (e.g., a disease

or disorder delineated herein), lessen the severity of the disease or improve the symptoms associated with the disease.

[13] “Disease” means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.

[14] It will be recognized that some variation of natural isotopic abundance occurs in a synthesized compound depending upon the origin of chemical materials used in the synthesis. Thus, a preparation of dimebolin will inherently contain small amounts of deuterated isotopologues. The concentration of naturally abundant stable hydrogen and carbon isotopes, notwithstanding this variation, is small and immaterial as compared to the degree of stable isotopic substitution of compounds of this invention. See, for instance, Wada E et al., *Seikagaku* 1994, 66:15; Gannes LZ et al., *Comp Biochem Physiol Mol Integr Physiol* 1998, 119:725.

[15] In the compounds of this invention any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Also unless otherwise stated, when a position is designated specifically as “D” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 50.1% incorporation of deuterium).

[16] The term “isotopic enrichment factor” as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope.

[17] In other embodiments, a compound of this invention has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[18] The term “isotopologue” refers to a species that differs from a specific compound of this invention only in the isotopic composition thereof.

[19] The term “compound,” when referring to a compound of this invention, refers to a collection of molecules having an identical chemical structure, except that there may be isotopic variation among the constituent atoms of the molecules. Thus, it will be clear to those of skill in the art that a compound represented by a particular chemical structure containing indicated deuterium atoms, will also contain lesser amounts of isotopologues having hydrogen atoms at one or more of the designated deuterium positions in that structure. The relative amount of such isotopologues in a compound of this invention will depend upon a number of factors including the isotopic purity of deuterated reagents used to make the compound and the efficiency of incorporation of deuterium in the various synthesis steps used to prepare the compound. However, as set forth above the relative amount of such isotopologues *in toto* will be less than 49.9% of the compound. In other embodiments, the relative amount of such isotopologues *in toto* will be less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5% of the compound.

[20] The invention also provides salts of the compounds of the invention.

[21] A salt of a compound of this invention is formed between an acid and a basic group of the compound, such as an amino functional group, or a base and an acidic group of the compound, such as a carboxyl functional group. According to another embodiment, the compound is a pharmaceutically acceptable acid addition salt.

[22] The term “pharmaceutically acceptable,” as used herein, refers to a component that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A “pharmaceutically acceptable salt” means any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention. A “pharmaceutically acceptable counterion” is an ionic portion of a salt that is not toxic when released from the salt upon administration to a recipient.

[23] Acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid, as well as organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid, as well as related inorganic and organic acids. Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylene sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β -hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and other salts. In one embodiment, pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and especially those formed with organic acids such as maleic acid.

[24] The compounds of the present invention (e.g., compounds of Formula I), may contain an asymmetric carbon atom, for example, as the result of deuterium substitution or otherwise. As such, compounds of this invention can exist as either individual enantiomers, or mixtures of the two enantiomers. Accordingly, a compound of the present invention may exist as either a racemic mixture or a scalemic mixture, or as individual respective stereoisomers that are substantially free from another possible stereoisomer. The term "substantially free of other stereoisomers" as used herein means less than 25% of other stereoisomers, preferably less than 10% of other stereoisomers, more preferably less than 5% of other stereoisomers and most preferably less than 2%

of other stereoisomers are present. Methods of obtaining or synthesizing an individual enantiomer for a given compound are known in the art and may be applied as practicable to final compounds or to starting material or intermediates.

[25] Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.


[26] The term “stable compounds,” as used herein, refers to compounds which possess stability sufficient to allow for their manufacture and which maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., formulation into therapeutic products, intermediates for use in production of therapeutic compounds, isolatable or storable intermediate compounds, treating a disease or condition responsive to therapeutic agents).

[27] “D” and “d” both refer to deuterium. “Stereoisomer” refers to both enantiomers and diastereomers. “Tert”, “t”, and “t-” each refer to tertiary. “US” refers to the United States of America.

[28] Throughout this specification, a variable may be referred to generally (e.g., “each R”) or may be referred to specifically (e.g., R¹, R², R³, etc.). Unless otherwise indicated, when a variable is referred to generally, it is meant to include all specific embodiments of that particular variable.

THERAPEUTIC COMPOUNDS

[29] The present invention provides a compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

each R is independently selected from CH₃, CD₂H, CDH₂ and CD₃;

each X is independently selected from H and D;

each Y is independently selected from H and D;

each Z is independently selected from H and D; and

when each R is CH₃, at least one X, Y or Z is D.

[30] In one embodiment, each X¹ is the same; each X² is the same; each X³ is the same; each Y is the same; and each Z is the same.

[31] In another embodiment, each X¹, X², and X³ is hydrogen.

[32] In another embodiment, each X¹, X², and X³ is deuterium.

[33] In another embodiment, each R is independently selected from CH₃ and CD₃. In one aspect of this embodiment, each X is D; each Y is the same; and each Z is the same.

[34] Specific examples of compounds of Formula I where each X is D are shown in Table 1 below.

Table 1: Exemplary Embodiments of Formula I

Compound	R ¹	R ²	R ³	each Y	each Z
100	CD ₃	CD ₃	CD ₃	D	D
101	CD ₃	CD ₃	CD ₃	D	H
102	CD ₃	CD ₃	CD ₃	H	D
103	CD ₃	CD ₃	CH ₃	D	D
104	CD ₃	CD ₃	CH ₃	D	H
105	CD ₃	CD ₃	CH ₃	H	D
106	CD ₃	CH ₃	CD ₃	D	D
107	CD ₃	CH ₃	CD ₃	D	H
108	CD ₃	CH ₃	CD ₃	H	D
109	CH ₃	CD ₃	CD ₃	D	D
110	CH ₃	CD ₃	CD ₃	D	H
111	CH ₃	CD ₃	CD ₃	H	D
112	CH ₃	CH ₃	CD ₃	D	D
113	CH ₃	CH ₃	CD ₃	D	H
114	CH ₃	CH ₃	CD ₃	H	D
115	CH ₃	CD ₃	CH ₃	D	D
116	CH ₃	CD ₃	CH ₃	D	H
117	CH ₃	CD ₃	CH ₃	H	D
118	CD ₃	CH ₃	CH ₃	D	D

Compound	R ¹	R ²	R ³	each Y	each Z
119	CD ₃	CH ₃	CH ₃	D	H
120	CD ₃	CH ₃	CH ₃	H	D
121	CH ₃	CH ₃	CH ₃	D	D
122	CH ₃	CH ₃	CH ₃	D	H
123	CH ₃	CH ₃	CH ₃	H	D
124	CD ₃	CD ₃	CD ₃	H	H
125	CD ₃	CH ₃	CD ₃	H	H
126	CD ₃	CD ₃	CH ₃	H	H
127	CH ₃	CD ₃	CD ₃	H	H
128	CH ₃	CH ₃	CD ₃	H	H
129	CH ₃	CD ₃	CH ₃	H	H
130	CD ₃	CH ₃	CH ₃	H	H
131	CH ₃	CH ₃	CH ₃	H	H

or pharmaceutically acceptable salts thereof.

[35] In another set of embodiments, any atom not designated as deuterium in any of the embodiments set forth above is present at its natural isotopic abundance.


[36] The synthesis of compounds of Formula I can be readily achieved by synthetic chemists of ordinary skill by reference to the Exemplary Synthesis disclosed herein.

Relevant procedures and intermediates are disclosed, for instance in patent publication SU 1138164 A1, Vinogradova, EV et al, Zhurnal Obshchei Khimii 1962, 32:1550, United States patent 3,409,628 and PCT publication WO 2008060190.


[37] Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure.

EXEMPLARY SYNTHESIS

[38] Methods for synthesizing compounds of Formula I are depicted in Scheme 1 and subsequent schemes.

[39] Scheme 1. Synthesis of Compounds of Formula I.

[40] According to Scheme 1, a compound of Formula I can be prepared by treating an appropriately deuterated p-tolyl-hydrazine **10** with an appropriately deuterated piperidin-4-one **11** in the presence deuterated sulfuric acid according to the procedure described by Vinogradova, EV et al, Zhurnal Obshchei Khimii 1962, 32: 1550-1556 provides a compound of Formula I.


[41] Scheme 2. Synthesis of a p-Tolyl-hydrazine **10**.

[42] Scheme 2 depicts the synthesis of deuterated p-tolyl-hydrazine **10**. Thus, treatment of an appropriately deuterated aniline **20** with an appropriately deuterated 3-pyridyl-acetic acid **21** in the presence of *N*-Ethyl-*N'*-(3-dimethylaminopropyl)carbodiimide ("EDC"), 1-hydroxybenzotriazole hydrate ("HOBt"), and *N*-methylmorpholine ("NMM") according to the procedure described in Korosec, T et al, *Biorg Med Chem* 2008, 16: 209-221 gives the deuterated amide **22**. Subsequent reduction of the amide **22** using deuterated borane or borane, again according to protocol of Korosec, T et al, *supra*, affords the appropriately deuterated (1-p-tolylhydrazinyl)ethylpyridine **23**. Treatment of that intermediate **23** with sodium nitrite in the presence of deuterium chloride in D_2O according to the procedure described by Vinogradova, EV et al, *Zhurnal Obshchei Khimii* 1962, 32: 1550-1556 affords the *N*-nitroso-amine **24**. Reduction of the *N*-nitroso-amine **24** is

accomplished by treatment with zinc in the presence of d_1 -acetic acid and D_2O according to the procedure described by in US 3,409,628 to afford the desired deuterated p-tolyl-hydrazine derivative **10**.


[43] Specific anilines of **20** useful in Scheme 2 are commercially available.


[44] Scheme 3. Synthesis of 3-Pyridyl-acetic acid **21**.



[45] Scheme 3 depicts the synthesis of a deuterated 3-pyridyl-acetic acid of **21**. Thus, treatment of commercially available 6-methyl-3-pyridineacetic acid **50** with sodium deuteroxide in D_2O at $100\text{ }^{\circ}\text{C}$ according to the procedure described by Foote, CS et al, J Am Chem Soc 1990, 112: 3607-3614 affords the desired 2,2-dideutero-2-(6-(trideuteriomethyl)pyridin-3-yl)acetic acid **21**.

[46] Scheme 4. Synthesis of a Deuterated Piperidin-4-one **11**.





[47] Scheme 4 depicts the synthesis of deuterated piperidin-4-one **11**. Thus, treatment of commercially available methyl acrylate-d₆ **30** with an appropriately deuterated primary amine **31** according to the procedure described in Chinese patent publication CN 1590387A gives the appropriately deuterated amino-diester **32**. Dieckmann cyclization of the amino ester **32** is accomplished by treatment with sodium deuteromethoxide in MeOD using the protocol in CN 1590387A to give the appropriately deuterated β-keto-ester **33**. Finally, saponification and decarboxylation of the β-keto-ester **33** with sodium deuterioxide in D₂O according to the procedures in CN 1590387A affords an appropriately deuterated piperidin-4-one **11**.

[48] The specific approaches and compounds shown above are not intended to be limiting. The chemical structures in the schemes herein depict variables that are hereby defined commensurately with chemical group definitions (moieties, atoms, etc.) of the corresponding position in the compound formulae herein, whether identified by the same variable name (i.e., R¹, R², R³, etc.) or not. The suitability of a chemical group in a compound structure for use in the synthesis of another compound is within the knowledge of one of ordinary skill in the art.

[49] Additional methods of synthesizing compounds of Formula I and their synthetic precursors, including those within routes not explicitly shown in schemes herein, are within the means of chemists of ordinary skill in the art. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the applicable compounds are known in the art and include, for example, those described in Larock R, *Comprehensive Organic Transformations*, VCH Publishers (1989); Greene TW et al., *Protective Groups in Organic Synthesis*, 3rd Ed.,

John Wiley and Sons (1999); Fieser L et al., *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and Paquette L, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995) and subsequent editions thereof.

[50] Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds.

COMPOSITIONS

[51] The invention also provides pyrogen-free pharmaceutical compositions comprising an effective amount of a compound of Formula I (e.g., including any of the formulae herein), or a pharmaceutically acceptable salt of said compound; and a pharmaceutically acceptable carrier. The carrier(s) are "acceptable" in the sense of being compatible with the other ingredients of the formulation and, in the case of a pharmaceutically acceptable carrier, not deleterious to the recipient thereof in an amount used in the medicament.

[52] Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[53] If required, the solubility and bioavailability of the compounds of the present invention in pharmaceutical compositions may be enhanced by methods well-known in the art. One method includes the use of lipid excipients in the formulation. See "Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs (Drugs and the Pharmaceutical Sciences)," David J. Hauss, ed. Informa Healthcare, 2007; and "Role of Lipid Excipients in Modifying Oral and Parenteral Drug

Delivery: Basic Principles and Biological Examples," Kishor M. Wasan, ed. Wiley-Interscience, 2006.

[54] Another known method of enhancing bioavailability is the use of an amorphous form of a compound of this invention optionally formulated with a poloxamer, such as LUTROLTM and PLURONICTM (BASF Corporation), or block copolymers of ethylene oxide and propylene oxide. See United States patent 7,014,866; and United States patent publications 20060094744 and 20060079502.

[55] The pharmaceutical compositions of the invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. In certain embodiments, the compound of the formulae herein is administered transdermally (e.g., using a transdermal patch or iontophoretic techniques). Other formulations may conveniently be presented in unit dosage form, e.g., tablets, sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. See, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, Baltimore, MD (20th ed. 2000).

[56] Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[57] In certain embodiments, the compound is administered orally. Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets, or tablets each containing a predetermined amount of the active ingredient; a powder or granules; a solution or a suspension in an aqueous liquid or a non-aqueous liquid; an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; packed in liposomes; or as a bolus, etc. Soft gelatin capsules can be useful for containing such suspensions, which may beneficially increase the rate of compound absorption.

[58] In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

[59] Compositions suitable for oral administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.

[60] Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

[61] Such injection solutions may be in the form, for example, of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic

acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.

[62] The pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

[63] The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, e.g.: Rabinowitz JD and Zaffaroni AC, US Patent 6,803,031, assigned to Alexza Molecular Delivery Corporation.

[64] Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For topical application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository

formulation or in a suitable enema formulation. Topically-transdermal patches and iontophoretic administration are also included in this invention.

[65] Application of the subject therapeutics may be local, so as to be administered at the site of interest. Various techniques can be used for providing the subject compositions at the site of interest, such as injection, use of catheters, trocars, projectiles, pluronic gel, stents, sustained drug release polymers or other device which provides for internal access.

[66] Thus, according to yet another embodiment, the compounds of this invention may be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents, or catheters. Suitable coatings and the general preparation of coated implantable devices are known in the art and are exemplified in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethylsiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition. Coatings for invasive devices are to be included within the definition of pharmaceutically acceptable carrier, adjuvant or vehicle, as those terms are used herein.

[67] According to another embodiment, the invention provides a method of coating an implantable medical device comprising the step of contacting said device with the coating composition described above. It will be obvious to those skilled in the art that the coating of the device will occur prior to implantation into a mammal.

[68] According to another embodiment, the invention provides a method of impregnating an implantable drug release device comprising the step of contacting said drug release device with a compound or composition of this invention. Implantable drug release devices include, but are not limited to, biodegradable polymer capsules or bullets, non-degradable, diffusible polymer capsules and biodegradable polymer wafers.

[69] According to another embodiment, the invention provides an implantable medical device coated with a compound or a composition comprising a compound of this invention, such that said compound is therapeutically active.

[70] According to another embodiment, the invention provides an implantable drug release device impregnated with or containing a compound or a composition comprising a compound of this invention, such that said compound is released from said device and is therapeutically active.

[71] Where an organ or tissue is accessible because of removal from the patient, such organ or tissue may be bathed in a medium containing a composition of this invention, a composition of this invention may be painted onto the organ, or a composition of this invention may be applied in any other convenient way.

[72] In another embodiment, a composition of this invention further comprises a second therapeutic agent. The second therapeutic agent may be selected from any compound or therapeutic agent known to have or that demonstrates advantageous properties when administered with a compound having the same mechanism of action as dimebolin. Such agents include those indicated as being useful in combination with dimebolin, including but not limited to, those described in PCT publications WO1997015225, WO2007041697, WO2007087425, WO2008036410, WO2008051599, WO2008069963 and WO2008073231.

[73] Preferably, the second therapeutic agent is an agent useful in the treatment or prevention of a disease or condition selected from chronic pain, neuropathic pain, cerebrovascular disorders, Alzheimer's disease, Huntington's disease, ALS, cognitive disorders, and dementia.

[74] According to one embodiment, the second therapeutic agent is selected from an acetylcholinesterase inhibitor, a butyrylcholinesterase inhibitor, an acetylcholine receptor agonist, a NMDA receptor antagonist, an inhibitor of amyloid A peptide or amyloid plaque, a phosphodiesterase 5 (PDE5) inhibitor, a phosphodiesterase 4 (PDE4) inhibitor, a monoamine oxidase inhibitor, a VEGF protein, a trophic growth factor, a HIF activator, a HIF prolyl 4-hydroxylases inhibitor, an anti-apoptotic compound, an ADNP agonist or analog, an ADNF agonist or analog, an activator of an AMPA-type

glutamate receptor, a serotonin 5-HT_{1A} receptor agonist, a serotonin 1A receptor antagonist, a nicotinic α -7 receptor agonist, a neuronal L-type calcium channel modulator, a 5-HT₄ receptor agonist, and an anti-inflammatory agent.

[75] In another embodiment, the second therapeutic agent is selected from donepezil, rivastigmine, galantamine, memantine, or a pharmaceutically acceptable salt of any of the foregoing.

[76] In yet another embodiment, the second therapeutic agent is donepezil hydrochloride.

[77] In another embodiment, the invention provides separate dosage forms of a compound of this invention and one or more of any of the above-described second therapeutic agents, wherein the compound and second therapeutic agent are associated with one another. The term “associated with one another” as used herein means that the separate dosage forms are packaged together or otherwise attached to one another such that it is readily apparent that the separate dosage forms are intended to be sold and administered together (within less than 24 hours of one another, consecutively or simultaneously).

[78] In the pharmaceutical compositions of the invention, the compound of the present invention is present in an effective amount. As used herein, the term “effective amount” refers to an amount which, when administered in a proper dosing regimen, is sufficient to treat the target disorder.

[79] The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described in Freireich et al., (1966) Cancer Chemother. Rep 50: 219. Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 1970, 537.

[80] In one embodiment, an effective amount of a compound of this invention can range from 1 mg to 500 mg per day. In another embodiment, an effective amount of a compound of this invention can range from 10 mg to 100 mg per day. In another embodiment, an effective amount of a compound of this invention can range from 20

mg to 60 mg per day. A daily amount can be administered in from 1 to 3 separate doses per day.

[81] Effective doses will also vary, as recognized by those skilled in the art, depending on the diseases treated, the severity of the disease, the route of administration, the sex, age and general health condition of the patient, excipient usage, the possibility of co-usage with other therapeutic treatments such as use of other agents and the judgment of the treating physician. For example, guidance for selecting an effective dose can be determined by reference to the amounts used safely in clinical trials and/or prescribing information for dimebolin.

[82] For pharmaceutical compositions that comprise a second therapeutic agent, an effective amount of the second therapeutic agent is between about 20% and 100% of the dosage normally utilized in a monotherapy regime using just that agent. Preferably, an effective amount is between about 70% and 100% of the normal monotherapeutic dose. The normal monotherapeutic dosages of these second therapeutic agents are well known in the art. *See, e.g.,* Wells et al., eds., *Pharmacotherapy Handbook*, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); *PDR Pharmacopoeia*, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000), each of which references are incorporated herein by reference in their entirety.

[83] It is expected that some of the second therapeutic agents referenced above will act synergistically with the compounds of this invention. When this occurs, it will allow the effective dosage of the second therapeutic agent and/or the compound of this invention to be reduced from that required in a monotherapy. This has the advantage of minimizing toxic side effects of either the second therapeutic agent or a compound of this invention, synergistic improvements in efficacy, improved ease of administration or use and/or reduced overall expense of compound preparation or formulation.

METHODS OF TREATMENT

[84] According to one embodiment, the invention provides a method of treating a disease that is beneficially treated by dimebolin in a patient in need thereof, comprising the step of administering to the patient an effective amount of a compound of Formula I

or a pharmaceutically acceptable salt thereof or a composition of this invention. Such diseases are well known in the art and include, but are not limited to, chronic pain, neuropathic pain, cerebrovascular disorders, cognitive disorders, dementia, Alzheimer's disease, Huntington's disease and ALS.

[85] In one particular embodiment, the method of this invention is used to treat a disease or condition selected from Alzheimer's disease and Huntington's disease in a patient in need thereof.

[86] Identifying a patient in need of such treatment can be in the judgment of a patient or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).

[87] In another embodiment, any of the above methods of treatment comprises the further step of co-administering to the patient in need thereof one or more second therapeutic agents. The choice of second therapeutic agent may be made from any second therapeutic agent known to be useful for co-administration with dimebolin. The choice of second therapeutic agent is also dependent upon the particular disease or condition to be treated. Examples of second therapeutic agents that may be employed in the methods of this invention are those set forth above for use in combination compositions comprising a compound of this invention and a second therapeutic agent.

[88] In particular, the invention provides a method of treating Alzheimer's disease in a patient in need thereof comprising the step of co-administering to the patient a pharmaceutically acceptable composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a second therapeutic agent selected from donepezil, rivastigmine, galantamine, memantine, or a pharmaceutically acceptable salt of any of the foregoing. In one particular aspect, the second therapeutic agent is donepezil hydrochloride.

[89] The term "co-administered" as used herein means that the second therapeutic agent may be administered together with a compound of this invention as part of a single dosage form (such as a composition of this invention comprising a compound of the invention and an second therapeutic agent as described above) or as separate, multiple dosage forms. Alternatively, the additional agent may be administered prior

to, consecutively with, or following the administration of a compound of this invention. In such combination therapy treatment, both the compound of this invention and the second therapeutic agent(s) are administered by conventional methods. The administration of a composition of this invention, comprising both a compound of the invention and a second therapeutic agent, to a patient does not preclude the separate administration of that same therapeutic agent, any other second therapeutic agent or any compound of this invention to said patient at another time during a course of treatment.

[90] Effective amounts of these second therapeutic agents are well known to those skilled in the art and guidance for dosing may be found in patents and published patent applications referenced herein, as well as in Wells et al., eds., *Pharmacotherapy Handbook*, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); *PDR Pharmacopoeia*, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000), and other medical texts. However, it is well within the skilled artisan's purview to determine the second therapeutic agent's optimal effective-amount range.

[91] In one embodiment of the invention, where a second therapeutic agent is administered to a subject, the effective amount of the compound of this invention or pharmaceutically acceptable salt thereof is less than its effective amount would be where the second therapeutic agent is not administered. In another embodiment, the effective amount of the second therapeutic agent is less than its effective amount would be where the compound of this invention is not administered. In this way, undesired side effects associated with high doses of either agent may be minimized. Other potential advantages (including without limitation improved dosing regimens and/or reduced drug cost) will be apparent to those of skill in the art.

[92] In yet another aspect, the invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof alone or together with one or more of the above-described second therapeutic agents in the manufacture of a medicament, either as a single composition or as separate dosage forms, for treatment or prevention in a patient of a disease, disorder or symptom set forth above. Another aspect of the

invention is a compound of Formula I for use in the treatment or prevention in a patient of a disease, disorder or symptom thereof delineated herein.

[93] In one aspect, the compound of Formula I or pharmaceutically acceptable salt thereof or a composition of the invention is for use in treating a disease or condition selected from chronic pain, neuropathic pain, cerebrovascular disorders, cognitive disorders, dementia, Alzheimer's disease, Huntington's disease and ALS. In one specific aspect of this embodiment, the compound of Formula I or pharmaceutically acceptable salt thereof or a composition of the invention is for use in treating a disease or condition selected from Alzheimer's disease and Huntington's disease.

[94] In another aspect, the compound of Formula I or pharmaceutically acceptable salt thereof or a composition of the invention is for use in treating Alzheimer's disease; and the compound or pharmaceutically acceptable salt thereof or composition is used in conjunction with a second therapeutic agent selected from a second therapeutic agent selected from donepezil, rivastigmine, galantamine, memantine, or a pharmaceutically acceptable salt of any of the foregoing. In one particular aspect, the compound or composition is used in conjunction with donepezil hydrochloride.

[95] The term "used in conjunction with" as used herein means administered simultaneously with, or administered within 24 hours of the subject composition.

Example 1. Evaluation of Metabolic Stability

[96] **Microsomal Assay:** Human liver microsomes (20 mg/mL) are obtained from Xenotech, LLC (Lenexa, KS). β -nicotinamide adenine dinucleotide phosphate, reduced form (NADPH), magnesium chloride (MgCl_2), and dimethyl sulfoxide (DMSO) are purchased from Sigma-Aldrich.

[97] **Determination of Metabolic Stability:** 7.5 mM stock solutions of test compounds are prepared in DMSO. The 7.5 mM stock solutions are diluted to 12.5-50 μM in acetonitrile (ACN). The 20 mg/mL human liver microsomes are diluted to 0.625 mg/mL in 0.1 M potassium phosphate buffer, pH 7.4, containing 3 mM MgCl_2 . The diluted microsomes are added to wells of a 96-well deep-well polypropylene plate in triplicate. A 10 μL aliquot of the 12.5-50 μM test compound is added to the

microsomes and the mixture is pre-warmed for 10 minutes. Reactions are initiated by addition of pre-warmed NADPH solution. The final reaction volume is 0.5 mL and contains 0.5 mg/mL human liver microsomes, 0.25-1.0 μ M test compound, and 2 mM NADPH in 0.1 M potassium phosphate buffer, pH 7.4, and 3 mM $MgCl_2$. The reaction mixtures are incubated at 37 °C, and 50 μ L aliquots are removed at 0, 5, 10, 20, and 30 minutes and added to shallow-well 96-well plates which contain 50 μ L of ice-cold ACN with internal standard to stop the reactions. The plates are stored at 4 °C for 20 minutes after which 100 μ L of water is added to the wells of the plate before centrifugation to pellet precipitated proteins. Supernatants are transferred to another 96-well plate and analyzed for amounts of parent remaining by LC-MS/MS using an Applied Bio-systems API 4000 mass spectrometer. The same procedure is followed for the non-deuterated counterpart of the compound of Formula I and the positive control, 7-ethoxycoumarin (1 μ M). Testing is done in triplicate.

[98] **Data analysis:** The *in vitro* $t_{1/2}$ s for test compounds are calculated from the slopes of the linear regression of % parent remaining (ln) vs incubation time relationship.

$$\text{in vitro } t_{1/2} = 0.693/k$$


$$k = -[\text{slope of linear regression of \% parent remaining(ln) vs incubation time}]$$

[99] Data analysis is performed using Microsoft Excel Software.

[100] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It will be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All the patents, journal articles and other documents discussed or cited above are herein incorporated by reference.

What is claimed is:

1. A compound of the formula:



, or a pharmaceutically acceptable salt thereof, wherein:

each R is independently selected from CH₃, CD₂H, CDH₂ and CD₃;

each X is independently selected from H and D;

each Y is independently selected from H and D;

each Z is independently selected from H and D; and

when each R is CH₃, at least one X, Y or Z is D.

2. The compound of claim 1, wherein:

each X¹ is the same;

each X² is the same;

each X³ is the same;

each Y is the same;

each Z is the same.

3. The compound of claim 1 or 2, wherein each X is the same.

4. The compound of claim 3, wherein each X is deuterium.

5. The compound of any one of claims 1 to 4, wherein each R is independently selected from CH₃ and CD₃.

6. The compound of claim 5, wherein each X is deuterium, the compound being selected from any one of the compounds set forth in the table below:

Compound	R ¹	R ²	R ³	each Y	each Z
100	CD ₃	CD ₃	CD ₃	D	D
101	CD ₃	CD ₃	CD ₃	D	H
102	CD ₃	CD ₃	CD ₃	H	D
103	CD ₃	CD ₃	CH ₃	D	D
104	CD ₃	CD ₃	CH ₃	D	H
105	CD ₃	CD ₃	CH ₃	H	D
106	CD ₃	CH ₃	CD ₃	D	D
107	CD ₃	CH ₃	CD ₃	D	H
108	CD ₃	CH ₃	CD ₃	H	D
109	CH ₃	CD ₃	CD ₃	D	D
110	CH ₃	CD ₃	CD ₃	D	H
111	CH ₃	CD ₃	CD ₃	H	D
112	CH ₃	CH ₃	CD ₃	D	D
113	CH ₃	CH ₃	CD ₃	D	H
114	CH ₃	CH ₃	CD ₃	H	D
115	CH ₃	CD ₃	CH ₃	D	D
116	CH ₃	CD ₃	CH ₃	D	H
117	CH ₃	CD ₃	CH ₃	H	D
118	CD ₃	CH ₃	CH ₃	D	D
119	CD ₃	CH ₃	CH ₃	D	H
120	CD ₃	CH ₃	CH ₃	H	D
121	CH ₃	CH ₃	CH ₃	D	D
122	CH ₃	CH ₃	CH ₃	D	H
123	CH ₃	CH ₃	CH ₃	H	D
124	CD ₃	CD ₃	CD ₃	H	H
125	CD ₃	CH ₃	CD ₃	H	H
126	CD ₃	CD ₃	CH ₃	H	H
127	CH ₃	CD ₃	CD ₃	H	H
128	CH ₃	CH ₃	CD ₃	H	H
129	CH ₃	CD ₃	CH ₃	H	H
130	CD ₃	CH ₃	CH ₃	H	H
131	CH ₃	CH ₃	CH ₃	H	H

or a pharmaceutically acceptable salt of the foregoing compounds.

7. The compound of any one of claims 1 to 6, wherein any atom not designated as deuterium is present at its natural abundance.
8. A pyrogen-free pharmaceutical composition comprising a compound of any one of claims 1 to 7; and a pharmaceutically acceptable carrier.
9. The compound of any one of claims 1 to 7, or the composition of claim 8 for use in the treatment of a disease or condition selected from chronic pain, neuropathic pain, cerebrovascular disorders, cognitive disorders, dementia, Alzheimer's disease, Huntington's disease and ALS.
10. The compound or composition of claim 9 for use in the treatment of a disease or condition selected from Alzheimer's disease and Huntington's disease.
11. The compound or composition of claim 9 for use in treating Alzheimer's disease, wherein the compound or composition is used in conjunction with a second therapeutic agent selected from donepezil, rivastigmine, galantamine, memantine, or a pharmaceutically acceptable salt of any of the foregoing.
12. The compound or composition of claim 9, wherein the second therapeutic agent is donepezil hydrochloride.
13. The composition of claim 8, further comprising a second therapeutic agent useful in the treatment of a disease or condition selected from chronic pain, neuropathic pain, cerebrovascular disorders, Alzheimer's disease, Huntington's disease, ALS, cognitive disorders, and dementia.
14. The composition of claim 13, wherein the second therapeutic agent is selected from an acetylcholinesterase inhibitor, a butyrylcholinesterase inhibitor, an acetylcholine receptor agonist, a NMDA receptor antagonist, an inhibitor of amyloid A

peptide or amyloid plaque, a phosphodiesterase 5 (PDE5) inhibitor, a phosphodiesterase 4 (PDE4) inhibitor, a monoamine oxidase inhibitor, a VEGF protein, a trophic growth factor, a HIF activator, a HIF prolyl 4-hydroxylases inhibitor, an anti-apoptotic compound, an ADNP agonist or analog, an ADNF agonist or analog, an activator of an AMPA-type glutamate receptor, a serotonin 5-HT_{1A} receptor agonist, a serotonin 1A receptor antagonist, a nicotinic alpha-7 receptor agonist, a neuronal L-type calcium channel modulator, a 5-HT₄ receptor agonist, and an anti-inflammatory agent.

15. The composition of claim 14, wherein the second therapeutic is selected from donepezil, rivastigmine, galantamine, memantine, or a pharmaceutically acceptable salt of any of the foregoing.

16. A method of treating a disease or condition selected from chronic pain, neuropathic pain, cerebrovascular disorders, cognitive disorders, dementia, Alzheimer's disease, Huntington's disease and ALS in a patient in need thereof, the method comprising the step of administering to the patient an effective amount of a composition of claim 8.

17. The method of claim 16, wherein the disease is selected from Alzheimer's disease and Huntington's disease.

18. The method of claim 16 or 17 comprising the additional step of co-administering to the patient in need thereof a second therapeutic agent selected from an acetylcholinesterase inhibitor, a butyrylcholinesterase inhibitor, an acetylcholine receptor agonist, a NMDA receptor antagonist, an inhibitor of amyloid A peptide or amyloid plaque, a phosphodiesterase 5 (PDE5) inhibitor, a phosphodiesterase 4 (PDE4) inhibitor, a monoamine oxidase inhibitor, a VEGF protein, a trophic growth factor, a HIF activator, a HIF prolyl 4-hydroxylases inhibitor, an anti-apoptotic compound, an ADNP agonist or analog, an ADNF agonist or analog, an activator of an AMPA-type glutamate receptor, a serotonin 5-HT_{1A} receptor agonist, a serotonin 1A receptor

antagonist, a nicotinic alpha-7 receptor agonist, a neuronal L-type calcium channel modulator, a 5-HT₄ receptor agonist, and an anti-inflammatory agent.

19. The method of claim 18, wherein the second therapeutic is selected from donepezil, rivastigmine, galantamine, memantine, or a pharmaceutically acceptable salt of any of the foregoing.

20. The method of claim 19, wherein the disease is Alzheimer's disease and the second therapeutic agent is donepezil hydrochloride.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/065872

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D471/04 A61K31/475 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 876 818 A2 (ZEFIROV NIKOLAI SERAFIMOVICH [RU]; AFANASIEV ANDREI ZAKHAROVICH [RU];) 11 November 1998 (1998-11-11) page 1, line 1 - page 4, line 32 page 6; table A; compound 10 claim 1	1-20
Y	----- WO 95/26325 A2 (ISOTECHNIKA INC [CA]) 5 October 1995 (1995-10-05) page 1, line 9 - line 15 page 19, line 8 - page 20, line 2 claim 1 ----- -/--	1-20

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

22 January 2010

Date of mailing of the international search report

03/02/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bissmire, Stewart

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/065872

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design" ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1-40, XP009086953 ISSN: 0065-2490 page 4, paragraph 2 - page 8, paragraph 2 -----	1-20
Y	MARTIN I BLAKE ET AL: "Studies with Deuterated drugs" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 64, no. 3, 1 March 1975 (1975-03-01), pages 367-391, XP009090019 ISSN: 0022-3549 the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2009/065872

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0876818	A2	11-11-1998	AT 229806 T 15-01-2003
			AU 7347496 A 15-05-1997
			CA 2269698 A1 01-05-1997
			DE 69625518 D1 30-01-2003
			DE 69625518 T2 04-09-2003
			DK 876818 T3 31-03-2003
			ES 2188793 T3 01-07-2003
			HK 1016893 A1 08-08-2003
			WO 9715225 A1 01-05-1997
			RU 2106864 C1 20-03-1998
			US 6187785 B1 13-02-2001
WO 9526325	A2	05-10-1995	AT 372966 T 15-09-2007
			AU 707748 B2 22-07-1999
			AU 1944195 A 17-10-1995
			BR 9507200 A 16-09-1997
			CA 2186371 A1 05-10-1995
			CN 1148843 A 30-04-1997
			DE 69535592 T2 12-06-2008
			EP 0751926 A1 08-01-1997
			ES 2293638 T3 16-03-2008
			JP 3696884 B2 21-09-2005
			JP 9510717 T 28-10-1997
			US 5846514 A 08-12-1998